TY - JOUR
T1 - Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
AU - Stravalaci, Matteo
AU - Pagani, Isabel
AU - Paraboschi, Elvezia Maria
AU - Pedotti, Mattia
AU - Doni, Andrea
AU - Scavello, Francesco
AU - Mapelli, Sarah N.
AU - Sironi, Marina
AU - Perucchini, Chiara
AU - Varani, Luca
AU - Matkovic, Milos
AU - Cavalli, Andrea
AU - Cesana, Daniela
AU - Gallina, Pierangela
AU - Pedemonte, Nicoletta
AU - Capurro, Valeria
AU - Clementi, Nicola
AU - Mancini, Nicasio
AU - Invernizzi, Pietro
AU - Bayarri-Olmos, Rafael
AU - Garred, Peter
AU - Rappuoli, Rino
AU - Duga, Stefano
AU - Bottazzi, Barbara
AU - Uguccioni, Mariagrazia
AU - Asselta, Rosanna
AU - Vicenzi, Elisa
AU - Mantovani, Alberto
AU - Garlanda, Cecilia
PY - 2022/2
Y1 - 2022/2
N2 - The humoral arm of innate immunity includes diverse molecules with antibody-like functions, some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID-19). The present study was designed to conduct a systematic investigation of the interaction of human humoral fluid-phase pattern recognition molecules (PRMs) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of 12 PRMs tested, the long pentraxin 3 (PTX3) and mannose-binding lectin (MBL) bound the viral nucleocapsid and spike proteins, respectively. MBL bound trimeric spike protein, including that of variants of concern (VoC), in a glycan-dependent manner and inhibited SARS-CoV-2 in three in vitro models. Moreover, after binding to spike protein, MBL activated the lectin pathway of complement activation. Based on retention of glycosylation sites and modeling, MBL was predicted to recognize the Omicron VoC. Genetic polymorphisms at the MBL2 locus were associated with disease severity. These results suggest that selected humoral fluid-phase PRMs can play an important role in resistance to, and pathogenesis of, COVID-19, a finding with translational implications.Stravalaci et al. examined recognition of SARS-CoV-2 by human soluble innate pattern recognition receptor. They report that pentraxin 3 and mannose-binding protein recognize viral nucleoprotein and spike, respectively. Mannose-binding lectin has antiviral activity, and human genetic polymorphisms of MBL2 are associated with more severe COVID-19.
AB - The humoral arm of innate immunity includes diverse molecules with antibody-like functions, some of which serve as disease severity biomarkers in coronavirus disease 2019 (COVID-19). The present study was designed to conduct a systematic investigation of the interaction of human humoral fluid-phase pattern recognition molecules (PRMs) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of 12 PRMs tested, the long pentraxin 3 (PTX3) and mannose-binding lectin (MBL) bound the viral nucleocapsid and spike proteins, respectively. MBL bound trimeric spike protein, including that of variants of concern (VoC), in a glycan-dependent manner and inhibited SARS-CoV-2 in three in vitro models. Moreover, after binding to spike protein, MBL activated the lectin pathway of complement activation. Based on retention of glycosylation sites and modeling, MBL was predicted to recognize the Omicron VoC. Genetic polymorphisms at the MBL2 locus were associated with disease severity. These results suggest that selected humoral fluid-phase PRMs can play an important role in resistance to, and pathogenesis of, COVID-19, a finding with translational implications.Stravalaci et al. examined recognition of SARS-CoV-2 by human soluble innate pattern recognition receptor. They report that pentraxin 3 and mannose-binding protein recognize viral nucleoprotein and spike, respectively. Mannose-binding lectin has antiviral activity, and human genetic polymorphisms of MBL2 are associated with more severe COVID-19.
KW - MANNOSE-BINDING LECTIN
KW - LONG PENTRAXIN PTX3
KW - WHOLE-GENOME ASSOCIATION
KW - LENTIVIRAL VECTORS
KW - PROTEIN
KW - POLYMORPHISMS
KW - MBL
KW - AFRICAN
KW - DOMAIN
KW - CELLS
U2 - 10.1038/s41590-021-01114-w
DO - 10.1038/s41590-021-01114-w
M3 - Journal article
C2 - 35102342
VL - 23
SP - 275
EP - 286
JO - Nature Immunology
JF - Nature Immunology
SN - 1529-2908
IS - 2
ER -